Milmet Oftho v Allergan: Why World-First Use Wins in Pharma

OCUFLOX. An eye medication sold by US pharma major Allergan across world markets — and, separately, by Indian company Milmet Oftho in India. Allergan had never sold a bottle in India and held no Indian registration for the mark.

Allergan still won. In 2004, the Supreme Court held that for medicinal products, the party that was first in the world market can stop a later Indian adopter — even without Indian sales. For pharma trademarks, the case redrew the map.

Here is what happened in Milmet Oftho Industries v Allergan Inc, why medicines get a stricter test than any other product, and what it means for every Indian pharma founder naming a product in 2026.

The OCUFLOX collision

Allergan used OCUFLOX for an ophthalmic preparation — an eye-care product built around the antibiotic ofloxacin — and sold it in multiple countries. Milmet Oftho, an Indian pharmaceutical company, began marketing its own eye preparation in India under the identical name.

Allergan sued for passing off in the Calcutta High Court. It could not sue for infringement: it had no Indian registration. And its passing-off claim faced an obvious objection — how do you have goodwill in a market where you have never sold?

The dispute travelled through the High Court’s two tiers and up to the Supreme Court, which came down on Allergan’s side and restrained the Indian company’s use of the mark.

The holding: first in the world market

The Court’s central move was to widen the frame. For pharmaceutical products, it held, the mere fact that the claimant has not used the mark in India is irrelevant if it was first in the world market. What matters is who adopted and used the mark first anywhere — not who reached the Indian chemist’s shelf first.

On the evidence, Allergan’s use of OCUFLOX preceded Milmet’s. That settled it. An identical mark, on a medicine for the same organ, from a later adopter, could not stand.

In pharma, the world market is the market.

Note what the Court did not require: no Indian sales, no Indian advertising, no proof that Indian doctors knew the brand. For medicines, priority in world commerce did the work that local goodwill does in an ordinary passing-off case.

Why medicines get the strictest test

Three years earlier, in Cadila Health Care v Cadila Pharmaceuticals (2001), the Supreme Court had already warned that confusion between medicinal products is not a commercial inconvenience — it is a health hazard. Doctors’ handwriting, crowded pharmacy counters, patients asking for a brand from memory: every link in the chain can turn similarity into a dispensing error.

Milmet Oftho applied that logic to priority. If two companies sell same-name medicines in different countries, the danger is not abstract. Doctors trained abroad prescribe by the names they know. Patients travel. Medical literature crosses borders even when products do not.

• Exacting comparison. Marks for medicines are compared with far less tolerance for similarity than marks for ordinary goods.
• Global frame for priority. First use anywhere in the world can defeat first use in India — for pharma.
• Public interest overrides. The test protects patients first and traders second.

A confused buyer of shoes loses money. A confused buyer of medicine can lose much more.

The guardrail: no throttling Indian companies

The Court added a caution that is quoted almost as often as the holding. Multinational corporations that have no intention of introducing their product in India should not be allowed to throttle Indian companies with foreign trademark portfolios.

The world-first rule, in other words, is not a blank cheque for foreign brand owners. A claimant must be a genuine first user in world commerce with a real connection to — or a real prospect of entering — the Indian market. A dormant foreign registration collected for leverage is not the same thing as OCUFLOX, an actively marketed medicine.

That balance matters for both sides of the aisle. Indian companies get protection from ambush by paper portfolios. Foreign innovators get protection from name-jacking. The losers are free-riders in either direction.

Where Milmet sits in the trans-border reputation story

Milmet is one chapter in a longer arc. In the Whirlpool case (1996), Indian courts protected a foreign brand whose reputation had spilled into India through advertising, even with minimal local sales. Milmet went further for medicines: world-first use mattered without proof of Indian reputation at all.

Then in 2017, the Supreme Court’s Toyota v Prius decision pulled general passing-off law back toward territoriality — a foreign claimant must normally prove reputation among Indian consumers. But Prius was about car accessories. Milmet’s strict approach for medicinal products stands on its own public-health footing, and courts continue to treat pharma marks as a special category.

The practical reading for 2026: for ordinary goods, reputation in India decides; for medicines, world-first use carries decisive weight. This sits alongside the protection given to famous marks generally — explained in our guide to well-known trademarks under Section 11.

Territory limits most trademarks. Medicine limits the exceptions.

The 2026 playbook for pharma founders

1. Search globally, not just locally. A comprehensive trademark search and watch should cover the Indian register, WIPO’s Global Brand Database, and major pharma markets before you commit to a name.
2. File in India immediately. India is first-to-file, and trademark registration in Class 5 costs ₹4,500 per class in government fees for startups and MSMEs. Milmet protects world-first users; a registration protects you from everyone else.
3. File abroad before you export. If your molecule has export potential, a Madrid Protocol filing extends your Indian application to 130+ countries through one application.
4. Move fast on conflicts. Courts weigh delay heavily in interim injunctions. If a same-name product surfaces, our IP litigation team can assess an enforcement strategy within days, not months.

Milmet’s rule cuts both ways: it can rescue your brand abroad, or kill your launch at home.

OCUFLOX was one product name shared by two honest companies on two continents — and one of them had to stop. Search the world before you name the product, file the day the name clears, and never assume the Indian register tells the whole story.